CADL Logo

Candel Therapeutics, Inc. (CADL) 

NASDAQ$8.75
Market Cap
$389.16M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
53 of 924
Rank in Industry
38 of 527

CADL Insider Trading Activity

CADL Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$7,500,00013
Sells
$2,899,8233097

Related Transactions

Manning Paul Bdirector1$7.5M0$0$7.5M
Schoch CharlesSee Remarks0$04$267,781$-267,781
Nichols William GarrettChief Medical Officer0$05$356,318$-356,318
Barone FrancescaChief Scientific Officer0$05$477,223$-477,223
Aguilar-Cordova Estuardo10 percent owner0$06$486,476$-486,476
Tyagarajan SeshuChief Technology Officer0$05$491,658$-491,658
Tak Paul PeterChief Executive Officer0$05$820,367$-820,367

About Candel Therapeutics, Inc.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of …

Insider Activity of Candel Therapeutics, Inc.

Over the last 12 months, insiders at Candel Therapeutics, Inc. have bought $7.5M and sold $2.9M worth of Candel Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Candel Therapeutics, Inc. have bought $7.46M and sold $2.9M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Manning Paul B (director) — $7.5M.

The last purchase of 1,250,000 shares for transaction amount of $7.5M was made by Manning Paul B (director) on 2024‑12‑16.

List of Insider Buy and Sell Transactions, Candel Therapeutics, Inc.

2025-01-15SaleTak Paul PeterChief Executive Officer
21,704
0.0476%
$7.22$156,811+0.94%
2025-01-15SaleBarone FrancescaChief Scientific Officer
13,534
0.0297%
$7.22$97,783+0.94%
2025-01-15SaleTyagarajan SeshuChief Technology Officer
14,322
0.0314%
$7.22$103,476+0.94%
2025-01-15SaleNichols William GarrettChief Medical Officer
10,428
0.0229%
$7.22$75,342+0.94%
2025-01-15SaleSchoch CharlesSee Remarks
9,511
0.0209%
$7.22$68,717+0.94%
2025-01-08SaleTak Paul PeterChief Executive Officer
21,172
0.0454%
$8.22$173,996-8.19%
2025-01-08SaleBarone FrancescaChief Scientific Officer
13,673
0.0293%
$8.22$112,367-8.19%
2025-01-08SaleTyagarajan SeshuChief Technology Officer
14,545
0.0312%
$8.22$119,534-8.19%
2025-01-08SaleNichols William GarrettChief Medical Officer
10,799
0.0231%
$8.22$88,749-8.19%
2025-01-08SaleSchoch CharlesSee Remarks
9,971
0.0214%
$8.22$81,944-8.19%
2024-12-16PurchaseManning Paul Bdirector
1.25M
3.786%
$6.00$7.5M+33.12%
2024-11-29SaleTak Paul PeterChief Executive Officer
48,847
0.1456%
$4.56$222,527+70.17%
2024-11-29SaleBarone FrancescaChief Scientific Officer
22,081
0.0658%
$4.56$100,592+70.17%
2024-11-29SaleTyagarajan SeshuChief Technology Officer
20,392
0.0608%
$4.56$92,898+70.17%
2024-11-29SaleNichols William GarrettChief Medical Officer
13,935
0.0415%
$4.56$63,482+70.17%
2024-10-15SaleAguilar-Cordova Estuardo10 percent owner
10,412
0.0279%
$6.03$62,784+17.82%
2024-10-14SaleAguilar-Cordova Estuardo10 percent owner
15,000
0.0401%
$6.02$90,300+16.00%
2024-10-11SaleAguilar-Cordova Estuardo10 percent owner
15,000
0.0403%
$6.05$90,750+15.03%
2024-10-03SaleAguilar-Cordova Estuardo10 percent owner
1,800
0.0055%
$6.85$12,330+0.22%
2024-10-02SaleAguilar-Cordova Estuardo10 percent owner
26,988
0.083%
$6.92$186,757-1.47%
Total: 49
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
Manning Paul Bdirector
1303752
2.9314%
$11.41M30<0.0001%
Tak Paul PeterChief Executive Officer
251912
0.5664%
$2.2M35<0.0001%
Barone FrancescaChief Scientific Officer
110673
0.2488%
$968,388.7515<0.0001%
Tyagarajan SeshuChief Technology Officer
96790
0.2176%
$846,912.5025<0.0001%
Martell Christopherdirector
152000
0.3418%
$1.33M30<0.0001%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$84,871,118
57
17.71%
$412.59M
$109,415,500
33
18.13%
$353.41M
$26,923,982
20
-17.22%
$407.13M
$73,222,926
18
60.19%
$406.4M
Candel Therapeutics, Inc.
(CADL)
$14,865,077
18
-28.56%
$389.16M

CADL Institutional Investors: Active Positions

Increased Positions52+173.33%13M+198.34%
Decreased Positions11-36.67%60,779-0.91%
New Positions21New8MNew
Sold Out Positions2Sold Out14,876Sold Out
Total Postitions71+136.67%20M+197.43%

CADL Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Fmr Llc$35,214.009.34%3.92M+4M+59,592.67%2024-12-31
Baker Bros. Advisors Lp$26,763.007.1%2.98M+3MNew2024-12-31
Acorn Capital Advisors, Llc$17,408.004.62%1.94M+2MNew2024-12-31
Northpond Ventures, Llc$17,369.004.61%1.94M00%2024-09-30
Braidwell Lp$14,360.003.81%1.6M+2MNew2024-12-31
Vanguard Group Inc$12,019.003.19%1.34M+392,885+41.52%2024-12-31
Blackrock, Inc.$10,626.002.82%1.18M+58,268+5.18%2024-12-31
Portolan Capital Management, Llc$6,765.001.8%753,745+753,745New2024-12-31
Halter Ferguson Financial Inc.$6,115.001.62%681,334+376,795+123.73%2024-12-31
State Street Corp$5,035.001.34%560,969+68,964+14.02%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.